Niagen Bioscience Inc reported in the third quarter of 2025 net earnings per share of $0.05 an increase by 150 % year on year from $0.02 and an improvement of 25 % from $0.04 realized in II. Quarter (Jun 30 2025).
third quarter of 2025
Earnings Per Share
Revenues
$ 0.05
$
34 Mill
$+0.03+150 %
$+8M+32.86 %
Niagen Bioscience Inc 's Revenue
rose by
32.86 % in third quarter of 2025 (Sep 30 2025) year on year,
to $34 million and
advanced by
9.22 % sequentially.
Niagen Bioscience Inc 's net income of $4.578 million in the third quarter of 2025 increased by 143.77 % from net earnings of $1.878 million achieved in III. Quarter a year ago.
Sequentially
net earnings grew by 26.85 % from net income of $3.609 million realized in previous quarter.
Niagen Bioscience Inc Inventories Inventories grew by 78.22 % to $19 million from III. Quarter a year ago, sequentially inventories rose by 30.44 %.
NAGE's Cash flow
In the third quarter of 2025 company's net cash flow was $4 million
Niagen Bioscience Inc
does not pay out common stock dividend.
In trailing twelve-month period Niagen Bioscience Inc earned $ 0.25 cash per share, on a free-cash flow basis
107.46 % of net earning per share.
Book value grew by 9.62 % sequentially to $0.82 per share, 160.62% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 0.81 per share from $ 0.74.
Company
issued 0.38 million shares or 0.44 % in Sep 30 2025.
Interest Coverage Ratio was 11.91.
Niagen Bioscience Inc
does not pay out common stock dividend.
In trailing twelve-month period Niagen Bioscience Inc had $ 0.25 cash flow per share, on a free-cash flow basis
107.46 % of net earning per share.
Book value grew by 9.62 % sequentially to $0.82 per share, 160.62% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 0.81 per share from $ 0.74.
Company
issued 0.38 million shares or 0.44 % in Sep 30 2025.
Interest Coverage Ratio was 11.91.
